Results
At time of diagnosis, 6-24% of patients with TC were reported to be azoospermic and 50% oligozoospermic. Without conducting semen analysis at diagnosis, these patients cannot be identified and may be at further risk of subfertility. Gonadotoxic therapies cause an overall decrease in male fertility by 30% and there is currently no method to predict which patients will become azoospermic after treatment. Patients with larger, more invasive tumours, however, are at greater risk of infertility from local tumour effects, and are also more likely to undergo several different type of therapy, which has further detrimental effects on conception rates. Most treatment-induced infertility recovers 2 years post-treatment, but paternity can be delayed during a couple's peak reproductive years. Semen cryopreservation remains the procedure of choice in preserving fertility, but the service is underused, with only 24% of patients banking sperm. Microdissection testicular sperm extraction (microTESE) at the time of orchidectomy (onco-microTESE) is a successful infertility treatment option for those found to be azoospermic or severely oligozoospermic at diagnosis, while microTESE may still retrieve sperm in azoospermic patients after chemotherapy.
Conclusion
The underutilisation of semen analysis and sperm cryopreservation results in the failure to identify the azoospermic or severely oligozoospermic patient at diagnosis who may benefit from fertility-preserving procedures, for example, onco-microTESE at the time of orchidectomy. Fertility preservation and counselling needs to be broached earlier in the TC treatment pathway and made a greater priority. Given the advances in treatment, more patients with TC are surviving and looking to return to a normal life.
Introduction
Testicular cancer (TC), although only accounting for 1% of all cancers, is the most common cancer in men of reproductive potential, with a peak incidence in men between the ages of 15 and 35 years. Since 1970, in the UK, the incidence of TC has risen by 90% [1] . The cure rates from TC have increased over the last 20 years; the UK average 10-year survival rate is now 98% [2] , with a 5-year survival rate for advanced TC of 73% [3] . Fertility preservation and infertility management is, therefore, becoming a greater focus of patient management. The European Association of Urology recommends all men are referred for semen analysis and cryopreservation prior to treatment [4] ; however, there are numerous barriers to sperm banking, including under-referral, an urgency to commence chemotherapy, and insufficient patient knowledge of the chemotherapy effects on fertility [5] . Not surprisingly, only 24% of childless men bank sperm prior to treatment [6] [7] [8] . Additionally, up to 24% [9] of patients with TC have been reported to be azoospermic prior to treatment. The population of patients who develop TC has a higher rate of subfertility compared with the general population [10] . TC itself may lead to subfertility [11] and the effects of gonadotoxic agents may lead to further defects to spermatogenesis [12] . The aim of the present paper was to: (i) evaluate the impact of TC on fertility; (ii) evaluate the impact of different treatment methods on fertility; (iii) evaluate the methods of fertility preservation at diagnosis; (iv) evaluate the management of the patient rendered infertile as a consequence of treatment; and (v) recommend changes in current guidelines and practice, including the future of tissue banking.
Methods
A search of Pubmed and Google Scholar was performed for the period 2000-2017, and additional articles were sought from reference lists of included publications. Only articles written in English and related to humans were included. The search criteria involved multiple searches with different key words, including: 'testicular cancer'; 'cryopreservation'; 'infertility'; 'chemotherapy'; and 'onco-TESE'.
Impact of Testicular Cancer on Fertility
Data on cryopreservation show that fewer than half of men with TC have normal sperm quality before treatment, and 10-35% are infertile [13] . The interaction between TC and infertility is a complex interplay of the following pathological and psychological mechanisms: patients may have an inherent risk of subfertility before tumour development as a result of testicular dysgenesis syndrome (TDS) [10] ; the tumour itself may cause local and systemic detrimental effects on fertility [14] ; the presence of testicular microlithiasis (TML) has been associated with TC and infertility [15, 16] ; the development of TC has a damaging influence on patients' body image and sexual functioning [17] , which may have an impact on patient fertility; all treatment methods for TC have a negative effect on spermatogenesis and fertility.
Inherent Subfertility Risk: Testicular Dysgenesis Syndrome
Intrinsic subfertility in TC is thought to originate as a part of TDS. A phenomenon first described in 2001 [10] , TDS depicts a set of conditions that are hypothesized to share the same aetiology and are related to environmental factors, genetic predispositions and intra-uterine growth disorders [18] . No definitive biological mechanism has been defined, but some epigenetic and genetic mechanisms have been described [19, 20] . Hypospadias, abnormal spermatogenesis, cryptorchidism and TC have been described as different manifestations of the same syndrome and it is thought that the risk of contracting TC increases with increasing severity of the syndrome [21] . Some observations that support this phenomenon are as follows: patients are almost five times more likely to be azoospermic with a history of cryptorchidism, TC has a tendency (67%) to involve the previously affected testis in unilateral cryptorchidism [11] and semen quality in the affected testis is poorer in men with germ cell tumours compared with other testis tumour types [18] .
Impact of the Tumour on Spermatogenesis
As well as an inherent risk of subfertility in patients with TC, the testicular tumour has local adverse effects on spermatogenesis. Particularly noteworthy evidence for this phenomenon is that the highest rate of spermatogenesis defects occurs closest to malignant tumours [22] , yet this effect is not observed in benign tumours [23] . Larger tumour size has been associated with decreased levels of spermatogenesis in the ipsilateral testis [24, 25] . Notably, seminomas and nonseminoma germ cell tumours >4 cm are associated with a significant decrease in spermatogenesis compared with tumours of <4 cm [26] . Additionally, in 24% of men with testicular germ cell tumours, defects in spermatogenesis have been observed in the unaffected, contralateral testis [27] , suggesting that TC has a systemic effect on fertility; or perhaps, this is further evidence of TDS at play. The complex interaction between TC and infertility makes it impossible to distinguish the exact pathogenesis of infertility in this setting.
Proposed mechanisms of tumour-induced subfertility include: (i) disruption of spermatogenesis from hormones secreted locally by the tumour, such as b-HCG, a-fetoprotein and lactate dehydrogenase (LDH), which are thought to raise levels of oestradiol in the testis; (ii) anti-sperm antibodies in the testis attributable to tumour induced testis-blood barrier damage; and (iii) disruption of the hypothalamic-pituitary axis by an over-or under-secretion of hormones from the testis [14, 20] . Indeed, some studies have shown significant negative correlations with levels of raised tumour makers (bHCG, a-fetoprotein, lactate dehydrogenase) and sperm count [24] . However, this finding is not consistent across the literature, and therefore it is not a reliable marker of impaired spermatogenesis [25] .
Testicular Microlithiasis
The presence of TML, a phenomenon of unknown aetiology, is characterized by calcifications in the tubules of the testis, which are often multiple, small and bilateral. TML is generally asymptomatic and an incidental finding [28] . TML and its relationship between TC and infertility is poorly understood and has been extensively debated in the literature. Some studies show that TML is statistically more common in men with TC [15] and infertile men [16] , but the reported incidence of TML in these conditions varies significantly. Whether TML acts as a precursor to either or both is unclear; TML remains an enigma [29] . Figure 1 summarizes and illustrates the multifaceted relationship between TC, spermatogenesis and infertility.
Psychological Impact of Testicular Cancer on Fertility
Perceived attractiveness, retaining fertility and having children are considered some of the most important aspects of good quality of life after TC treatment [30] . It has been reported anti-sperm bodies develop and consequently impair spermatogenesis [14] . (c) The testicular tumour can systemically interfere with the body's endocrine organs, including the pituitary and the hypothalamus. Interference can lead to an over, or under secretion of hormones, which can impair spermatogenesis [14] . (d) The psychological impact of testicular cancer and testicular cancer surgery leaves 50% of testicular cancer survivors with negative changes in body image [32] , which is linked to the reduction in patient sexual activity [17] . Depression and anxiety is also a reported longterm consequence of cancer [33] , which is associated with infertility [34] . (e) Testicular dysgenesis syndrome is a genetically predisposed phenomenon that encompasses a set of aetiologically related conditions, including impaired spermatogenesis and testicular cancer, suggesting testicular cancer patients have an inherent risk of subfertility [10] . (f) The presence of testicular microlithiasis (TML) could be associated with infertility [16] , but the mechanism is unknown. aFP, a-fetoprotein; FSH, follicular stimulating hormone; GnRH, gonadotrophic release hormone; LDH, lactate dehydrogenase; LH, luteinising hormone; TDS, testicular dysgenesis syndrome; TML, testicular microlithiasis.
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© 2018 The Authors BJU International © 2018 BJU International that the psychological impact of TC on sexual performance, pleasure and infertility is a concern for young men [31] . Approximately half of TC survivors have perceived negative changes in body image [32] , which has been shown to be statistically related to decreased sexual interest and reduced sexual activity, a phenomenon reported to affect 43% of survivors [17] . Additionally, depression and anxiety are reported long-term consequences of TC [33] , which can also have an impact on sexual activity levels [34] .
Testicular Cancer Treatment and Infertility
Surgery, which includes radical orchidectomy and retroperitoneal lymph node dissection (RPLND), chemotherapy and radiotherapy, has a potential detrimental impact on infertility. The majority of the effects are reversible, but the time interval to spermatogenesis recovery varies according to length, type and combination of treatment.
Surgery: Radial Orchidectomy
Although TC can cause impaired spermatogenesis by disruption of the hypothalamic-pituitary axis [35] , removal of the tumour does not necessarily result in an improvement in spermatogenesis. Pre-and post-orchidectomy semen analysis samples of 1158 patients with TC showed that sperm concentration significantly decreased after orchidectomy [11] ; however, this impairment usually recovers. One study reported that 40% of patients are oligozoospermic or azoospermic up to 3 weeks after unilateral orchidectomy, but a steady recovery of spermatogenesis is seen often 2-3 years after surgery [36] . The ability of spermatogenesis to recover has been associated with pre-surgical fertility marker levels: men with elevated FSH levels at diagnosis were less likely to recover [37, 38] . One study found that, 2 years postoperatively, 88% of men with normal baseline FSH were normospermic, compared with 29% in men with high baseline FSH [37] . A lack of routine analysis of the hormones relating to infertility (FSH/LH/testosterone) hampers advancement of our understanding of this complex interplay.
Surgery: Retroperitoneal Lymph Node Dissection
Damage to the lumbar plexus and splenic nerves during RPLND can cause retrograde or anejaculation, rendering the individual concerned infertile. RPLND is conducted with a nerve-sparing technique now as standard practice, with reported rates of ejaculatory function preservation of up to 100% [39] . Steiner et al. [40] , however, reported that 14% of their cohort had retrograde ejaculation with this technique, and RPLND is still the leading cause (90%) of anejaculation [41] . Fibrosis within the pelvis, caused by previous radiotherapy or other factors, can prevent visualization of the nerves intra-operatively. The greater the fibrosis in patients undergoing RPLND, the more likely surgeons are to abandon a nerve-sparing technique [42] , which leads to higher rates of permanent retrograde, or, more commonly, loss of antegrade ejaculation [43] .
In men who undergo surveillance after orchidectomy,~80% who attempt conception will be successful after 10-11 years and, after RPLND, success rates of 59% [44] and 78% [45] have been reported. The median time to natural conception after orchidectomy has been reported to be 18 months [37] .
Chemotherapy
Chemotherapy for TC is usually cisplatin-based combination therapy. Cisplatin is given with either bleomycin and etoposide (BEP) or with vinblastine and bleomycin [45, 46] . Additionally, seminomas and stage 1 disease can be treated with a single cycle of carboplatin [47] . High survival rates, even with advanced stage disease, are attributable to tumour chemo-and radio-sensitivity. As it crosses the testis-blood barrier and targets actively dividing cells, chemotherapy has a substantial detrimental impact on spermatogenesis, leading to oligo-and azoospermia, with a well established association between inability to conceive and cumulative chemotherapy dose [45, 48, 49] . The time to recovery of spermatogenesis is dependent on the type of agent used, the dose, the number of cycles and individual risk factors [12, 45, 49] . Recovery has been postulated to be more likely in men with normal pretreatment sperm counts [9] , but some studies contradict this suggestion [50, 51] .
Although BEP therapy alone is considered 'low risk' for affecting spermatogenesis, BEP combination therapy is considered 'medium risk' because of the cisplatin component [12, 52] . Bujan et al. [53] found that men receiving two or fewer BEP cycles had their motility count return to pre-treatment values after 12 months. Another study confirmed that spermatogenesis recovered within 2 years in the vast majority of patients, except those who received five or more cycles [50] . Azoospermia was seen in 37% of patients 3 months after chemotherapy, which subsequently dropped to 3% after 24 months [43] . Higher doses of chemotherapy (cisplatin ≥850 mg) significantly impair spermatogenesis, with only 29% of men having normozoospermia after 11 years in a study in 1191 TC survivors. For comparison, in the same study, 65% were normozoospermic after surgery alone [49] .
The natural conception rate after cisplatin-based therapy was reported to be 85% at 12-year follow up, with a significant difference in time delay to paternity between two cycles and four cycles of treatment [54] . In two larger studies, conception rates of 73-76% were observed after low-dose chemotherapy and 42-56% after high-dose chemotherapy [45, 49] . No difference was found between conception rates after BEP therapy and vinblastine and bleomycin therapy [45] . In comparison to surgery, the impact of orchidectomy alone on conception rates is the equivalent to the impact of two to three cycles of cisplatin-based therapy [54] .
Although there is an abundance of data reporting on the impact of BEP therapy, data reporting on the impact of carboplatin are sparse. Nevertheless, a recent study found that Prolonged azoospermia [16] [17] [18] Permanent azoospermia >95% >20
Leydig cell failure
Adapted from Trottmann et al. [55] .
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Radiotherapy
The testes are exquisitely sensitive to radiation. Less than 0.5 Gy can cause reversible oligozoospermia, while <3 Gy, leads to azoospermia, which may take up to 30 months to recover. Doses of up to 5 Gy, or fractionated doses of >2.5 Gy can lead to longer-lasting azoopsermia, while doses >16 Gy can lead to permanent azoospermia and Leydig cell dysfunction (Table 1 ) [55] .
Although the retroperitoneal lymph nodes are often the primary target of radiotherapy treatment, scatter radiation to the testis is the most common cause of testicular impairment from radiotherapy, with an estimated 2% of the total radiation dose given reaching the testis; however, with correct and adequate gonadal shielding, the dose received to the testis can be as low as 0.28% [56] .
Similarly to chemotherapy-induced azoospermia, radiotherapy-induced azoospermia recovers well and within 24 months. In one cohort, 6 months post radiotherapy 26% were azoospermic, compared with 6% after 24 months [43] . Brydøy et al. [45] found that 63% of men achieved paternity after dog-leg or L-field technique radiotherapy, with no statistical difference between radiation doses of <31, 31-36 and >36 Gy. Men who underwent para-aortic area radiation had a significantly better conception rate (82%) than those who underwent the dog-leg or L-field technique; however, the latter cohort was much smaller than the former, so this may not be a generalizable finding. The average conception rate in men who underwent radiotherapy treatment and were attempting to conceive was 66% after an average of 11 years [49] . The effects of radiotherapy on spermatogenesis have also been shown to be reversible, but in the few years after treatment spermatogenesis is likely to be impaired during a couple's fertile window, therefore decreasing the chance of paternity.
Combination Therapy
Several studies show that overall fertility decreases by 30% in men treated for TC [6, 57] . Of all men treated for TC, average paternity rates range from 66% to 71% [45, 54] and the average time to live birth is 4.8 years [58] . In one cohort, only 56% of men who tried to conceive after receiving chemotherapy and radiotherapy were successful [45] . The lowest reported fertility rates have been seen in men who underwent chemotherapy, followed by radical orchidectomy and RPLND [6, 58] , and the highest fertility rates were seen after orchidectomy and surveillance only [45, 49, 58] . Table 2 summarizes the paternity rates observed after differing treatment regimens, and Table 3 summarizes the factors during treatment that have been found to influence the likelihood of paternity after treatment.
DNA Damage
There is concern that cytotoxic treatments affect the quality of sperm DNA, thereby increasing the likelihood of teratogenicity and abnormalities in patients' offspring conceived after treatment [48, 59] ; however, this concept is not universally accepted [60] . Some investigators advise that men wait 12-18 months after completion of therapy to attempt conception [61] , whilst other groups advise to wait 6 months [60] .
DNA fragmentation is a marker of DNA damage, but also a biomarker of fertility, which is thought to be superior to conventional semen markers in predicting fertility potential. Raised DNA fragmentation, as quantitated by the DNA fragmentation index (DFI), is associated with decreased conception rates and early pregnancy loss [62] . Paoli et al. [51] found that after chemotherapy DFI increases significantly 
Negative predictors Positive predictors
History of cryptorchidism [11, 45] Age <29 years [45] High FSH pre orchiectomy [63] Pre-treatment fatherhood [45] Dry ejaculation [45] Age >35 years [70] Cumulative dose >850 mg cisplatin-based therapy [49] Increasing number of cisplatin-based therapy [50] Combined TC therapies [44, 45] Low sperm count at diagnosis [63] TC, testicular cancer.
© 2018 The Authors BJU International © 2018 BJU International 165 3 months post chemotherapy. At this time point, men had a mean DFI of 28% after one to two cycles of BEP, and 33% after three to four cycles; however, DFI returns to baseline after 9 months and there is a significant decrease at 12 and 24 months. Similar results were found after radiotherapy. Post-treatment DNA damage is greater in more advanced TC [51] ; however, there is no evidence to suggest that there is any increase in birth defects in children conceived after treatment [9] .
Preservation of Fertility Before Treatment

Cryopreservation
Uses of Cryopreservation
Despite TC survivor paternity rates of up to 70% [45] , there is no accurate mechanism to predict the likelihood of fatherhood after treatment [63] ; therefore, the consensus is that all men of reproductive age with TC should be offered semen cryopreservation (SCP) as the standard [63, 64] . Currently, however, only about a third of patients with TC bank sperm [6-8,65].
Cryopreservation is highly effective at preserving sperm, even in severely oligozoospermic samples. Indeed, in a study of cryopreservation samples from 523 men with TC, only 5.6% of the men had normozoospermia [66] . For those who fail to ejaculate and cryopreserve sperm because of erectile dysfunction or anxiety, transrectal electroejaculation is an option, but is not widely available and hardly ever used in practice [67] .
The percentage of men who use their sample for assisted conception varies between 3% and 20%, but most studies report that fewer than 10% eventually use their cryopreserved sperm [45, 63, 66, 68] . Of those who attempt assisted conception with SCP,~55% achieve paternity [63] . Despite a high proportion of seemingly 'redundant' referrals to SCP, as most men who bank sperm conceive naturally [63] , men with TC generally keep semen samples for longer than men with infertility, implying the service is valued [64] . The positive psychological impact of SCP on the fertility-conscious patient, who may not use their sperm sample, is difficult to quantify, but is equally an important use of SCP. Certainly, men who achieve paternity have a higher quality-of-life score than those who do not [30, 69] .
Timing of Cryopreservation
Average sperm concentration and total sperm count are significantly reduced in sperm samples after orchidectomy compared with pre-surgical values. In a cohort of 1 158 men with TC the mean semen concentration before orchidectomy was 32 9 10 6 /mL and 24 9 10 6 /mL after surgery [11] . There is general acceptance that SCP should be conducted before orchidectomy [63, 70] . Nevertheless, cryopreservation is preferentially undergone by patients after surgery [11] and many centres still conduct SCP prior to chemotherapy but after orchidectomy as standard [71] . Conducting semen analysis and cryopreservation before chemotherapy protects the sperm from subsequent incurred DNA damage, but conducting it prior to orchidectomy identifies the azoospermic or severely oligozoospermic patient, who could be considered for microdissection testicular sperm extraction (microTESE) at the time of orchidectomy (onco-microTESE; see below). Cryopreservation used as a platform to identify and therefore permit the planning of azoospermic patients' infertility management is important, as there is currently no predictive factors to reliably predict the azoospermic patient at diagnosis, nor, in fact, after treatment [49] . Achieving cryopreservation before orchidectomy can usually be achieved within 1 week and does not lead to any significant delay in cancer treatment. Delaying orchidectomy for 1 week to assess and secure fertility is not detrimental, and can be safely achieved in almost all cases. In those presenting with extensive, poor prognosis, metastatic disease, or signs of superior vena cava obstruction, time is more of the essence, and initialization of treatment should not be sufficiently delayed to allow fertility assessment and preservation.
Sperm Quality of Cryopreservation Samples
Freezing of sperm can have damaging effects on the quality of the sperm and may impact on assisted conception success. Men with seminomas and those with lower fresh total motile cell count are less likely to have to greater post-thaw total motile cell count than their counterparts, so extra vials should be considered in these men [72] . Additionally, those with raised a-fetoprotein, particularly above >1 000 ng/mL, and increasing tumour volume are more likely to have poorer semen quality and fail to cryopreserve [73] .
Attitudes and Barriers
Although the literature recommends that all men be offered sperm banking prior to undergoing gonadotoxic therapy [11, 74, 75] , only 24-30% of men with TC bank sperm [6, 7, 65] . Under-referral and lack of information to patients have been reported to be responsible for this low uptake [5, 8] . If offered, 50% of men are interested in SCP [63] . In 2002, it was found that only half of oncologists discussed SCP with <25% of suitable patients [8] . In 2010, one study reported that only 42% of oncologists routinely discussed cryopreservation with their patients [76] , and those with a poorer prognosis were less likely to be referred [77] . Demonstrably, the welldocumented shift to fertility management, mentioned so often in the literature, has not translated into clinical practice. In a >850 mg cisplatin cumulative dose has low paternity rates at 42% [49] and failure to recover spermatogenesis [49] Avoid conception 6 months posttreatment [90] microTESE if no recovery after 2 years Radiotherapy Direct toxic effect of radiation damage on testicular germ and Leydig cells 24% azoospermic after 6 months Recovery of azoospermia after 24 months [43] microTESE if no recovery after 2 years BEP, bleomycin and etoposide; microTESE, microdissection testicular sperm extraction; onco-microTESE, microdissection testicular sperm extraction at the time of orchidectomy; PESA, percutaneous epididymal sperm aspiration; RPLND, retroperitoneal lymph node dissection; SSR, surgical sperm retrieval; TESA, testicular sperm aspiration.
© 2018 The Authors BJU International © 2018 BJU International 167 study of 200 men, 70% did not undergo sperm banking for the following main reasons: lack of interest, 50%; anxiety about starting chemotherapy, 18%; not being offered it, 17%; and declining because of cost, 9% [65] . In the UK, the NHS covers the cost of SCP in TC, but the cost of cryopreservation in private practice, or in other countries, could be more than £300 for the initial sample freeze and another £300 for each year the sample remains stored [78] .
Surgical Sperm Retrieval: Role of Onco-microTESE
Failure to cryopreserve because of azoospermia preorchidectomy, or as a result of a pre-pubertal diagnosis where production of an ejaculated sample may not be possible are indications for testicular sperm extraction (TESE). Those with persistent azoospermia 2-3 years post chemotherapy or radiotherapy and those with severe oligozoospermia can also be considered for the procedure [71] . Conventional TESE was first described in 2003. The technique involves an incision into the tunica albuginea, followed by a surgical dissection of seminiferous tubules [79] . This technique uses random 'blind' sampling to find sperm. MicroTESE uses 915-20 magnification to select only the most dilated-looking tubules, which are more likely to harbour sperm. Tubules can then be frozen or used immediately for assisted reproductive technology [80] . There is wide consensus that the microTESE technique is superior to conventional TESE; the requirement for testicular tissue removal is reduced 70-fold [81] , thereby greatly minimizing testicular damage, there is a 1.5 greater chance of sperm retrieval [82] and there are fewer postoperative complications [83] . Good success of TESE has been reported post chemotherapy in several studies (Table 4 ).
The TESE technique can also be conducted earlier in the management pathway. Onco-microTESE involves sperm extraction from the excised testes at the time of orchidectomy [70, 84] . The aim of this procedure is to extract sperm from the regions of the affected testis, which are free of tumour. Areas of normal spermatogenesis have been reported in the affected cancerous testis in a number of studies (Table 5 ).
The onco-microTESE technique has the advantage of allowing maximum preservation of sperm from functional tissue that would have otherwise been lost on the histopathological analysis. This procedure may therefore negate the need to surgically retrieve sperm from the unaffected, contralateral testis, minimizing testis damage in those with both testis present. It also has a more significant role in fertility preservation in men with TC and azoospermia in a solitary testis, or in men with bilateral synchronous tumours with azoospermia.
In our own institution, we have been performing oncomicroTESE for the last 2 years; our data highlight the importance of the onco-microTESE technique in difficult scenarios. Overall, among 11 men with TC and azoospermia, sperm was found in seven. Two men in the series had bilateral synchronous tumours, and sperm was found in at least one testis of the two affected testes in both men. Five men had a solitary functioning testis, and sperm was found in three of these men (Table 6 ) [85] . All cases of onco-microTESE were completed within 1 week of receiving the referral, again highlighting how a focus on fertility preservation does not result in delays to cancer treatment.
Several studies, albeit with small cohorts, report oncomicroTESE success in TC. Most of these have used only a TESE technique in the affected or contralateral testis and not onco-microTESE, as described in Fig. 2 . Table 5 summarizes the outcomes described in these recent reports [71] .
Management of the Patient Rendered Infertile as a Consequence of Treatment
Post-Chemotherapy Azoospermia
MicroTESE can also be used to treat persistent azoospermia after chemotherapy. Men with TC have the best sperm retrieval rates (at 85%) compared with other testis neoplasms, most likely as a result of fewer gonadotoxic chemotherapeutic agents used in TC. FSH, testosterone, time since chemotherapy and age have not been associated with better or worse retrieval rates; only men exposed to alkylating agents had lower odds of sperm retrieval [5] . There are no published studies analysing patients with TC undergoing microTESE after chemotherapy specifically, but live birth rates resulting from microTESE and artificial insemination techniques post-chemotherapy of 27% [86] and 42% [5] have been recorded, which are similar to those obtained with intracytoplasmic injection using sperm obtained by microTESE in a non-cancer setting [87] .
Postchemotherapy-Retroperitoneal Lymph Node Dissection Retrograde and Anejaculation Management
Retrograde ejaculation and anejaculation can be treated in a stepwise fashion with four main therapies: pharmacological agents; catheterization; electrostimulation; and TESE.
Pharmacological treatment with the use of a-adrenergics, such as pseudoephedrine or imipramine, functions to increase the tone of the bladder neck and propel semen forward during ejaculation and is considered first-line therapy for retrograde ejaculation. If this fails, sperm can be harvested from a retrograde specimen bladder after alkalinization of the urine in order to prevent the toxic effect of the low urinary pH on sperm. Failing this, sperm can be taken directly from the testis For those with failure of emission, medical therapy has no role; therefore, Hsiao et al. [88] recommend retrograde semen analysis prior to treatment initiation. Electroejaculation under general anaesthesia allows successful semen retrieval in 90% of patients [88] ; however, this is not widely available.
Experimental Techniques
Restoring post-treatment natural fertility in patients with cancer is a current pioneering area of research in oncofertility management. The use of spermatogonal stem cells (SSCs) and pre-gonadotoxic therapy testicular tissue preservation with post treatment re-transplantation could be novel revolutionary methods to treat complex cases. This includes pre-pubertal patients with TC, for whom cryopreservation cannot be used, and patients with nonobstructive azoospermia for whom surgical sperm retrieval has been unsuccessful [84, 90] . Several centres worldwide are already offering SSC freezing and tissue cryopreservation, although the technology and science behind retrieving and storing these samples is far further advanced than the knowledge of how best to achieve fertility from reimplantation. A number of different fertility restoration strategies using SSCs have been proposed. These include the collection of cell suspensions of SSCs, with the aim of reintroducing them into testicular tissue after gonadotrophic therapy to try to restore natural spermatogenesis and fertility in vivo, and the use of tissue cultures of testicular tissue to develop sperm in in vitro organ cultures for use in assisted reproductive techniques. However, the proposed techniques are yet to be proven to be safe enough for clinical use.
Conclusions and Recommendations for Practice
The evidence regarding fertility preservation in men with TC portrays a worrying pattern; it is the most common cancer in men at their peak reproductive age;~50% have impaired fertility at presentation; 6-24% have azoospermia pre-treatment. While the advances in surgical and oncological management have been a great success, the negative impact of every treatment method of further impairing fertility is of even more concern to those surviving longer and those looking to return to a normal reproductive life.
The relationships between fertility and TC are complex. There is no definitive or reliable way to identify the patient who, at first presentation with cancer, will be most at risk of azoospermia, before or after treatment. Important indicators include a history of cryptorchidism, larger tumour size and higher tumour stage. The impact of raised tumour markers remains contentious and should not be considered as a marker of infertility in isolation.
A paradigm shift is needed in our approach to managing patients with TC. Function must be assessed and addressed at first presentation and before orchidectomy, in line with our approach to other organs. One would never contemplate operating on a kidney tumour, without knowing the renal function, or state of the healthy kidney. Why then do most urologists remove a testis for a man at their reproductive peak without fully assessing their testicular function and reproductive potential?
While guidelines suggest assessment of testicular function in patients with TC preoperatively, there is no dictum to make them an essential part of the patients' initial assessment or to adopt a patient-focused approach to the management of this problem. This must change. Likewise, there is no clear directive to ensure all patients are referred for semen analysis and cryopreservation prior to orchidectomy. Ensuring cryopreservation is completed preoperatively removes the negative surgical and psychological impact on fertility, and allows the detection of patients with azoospermia who may benefit from an onco-microTESE. To this end, a viral screen checking for hepatitis B and C and HIV should also be performed with the baseline bloods in anticipation of cryopreservation. A new pathway aimed at achieving the best oncological outcome while ensuring maximum fertility preservation is essential for optimizing care in men with TC (Fig. 3) .
